Crossmark Global Holdings Inc. Trims Stake in Qiagen (NYSE:QGEN)

Crossmark Global Holdings Inc. decreased its position in shares of Qiagen (NYSE:QGEN) by 32.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 38,469 shares of the company’s stock after selling 18,306 shares during the period. Crossmark Global Holdings Inc.’s holdings in Qiagen were worth $1,713,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in QGEN. American Century Companies Inc. grew its holdings in shares of Qiagen by 34.2% during the 2nd quarter. American Century Companies Inc. now owns 31,904 shares of the company’s stock worth $1,311,000 after acquiring an additional 8,130 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Qiagen by 57.0% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 9,723 shares of the company’s stock worth $400,000 after buying an additional 3,530 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Qiagen in the 2nd quarter worth approximately $362,000. Public Sector Pension Investment Board grew its stake in shares of Qiagen by 5.9% in the 2nd quarter. Public Sector Pension Investment Board now owns 92,993 shares of the company’s stock worth $3,809,000 after buying an additional 5,185 shares during the last quarter. Finally, Point72 DIFC Ltd grew its stake in shares of Qiagen by 53.7% in the 2nd quarter. Point72 DIFC Ltd now owns 6,066 shares of the company’s stock worth $249,000 after buying an additional 2,119 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th. Morgan Stanley restated an “equal weight” rating and issued a $48.00 price target (down previously from $50.00) on shares of Qiagen in a research note on Monday, January 6th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 price objective (up from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $51.50.

Qiagen Price Performance

NYSE QGEN opened at $45.86 on Friday. The business’s fifty day moving average price is $44.43 and its 200-day moving average price is $44.22. The stock has a market capitalization of $10.47 billion, a price-to-earnings ratio of 117.59, a PEG ratio of 3.51 and a beta of 0.37. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.93.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.